Many Cardiovascular Systems, Inc.(CSII) Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock. Cardiovascular Systems Inc was Initiated by Lake Street on Jan 30, 2017 to Buy, Price Target of the shares are set at $40.Company shares were Reiterated by Needham on Jan 26, 2017 to Buy, Raises Price Target to $ 32 from a previous price target of $27 .
Company has reported several Insider transactions to the SEC, on Nov 21, 2016, Leslie Trigg (director) sold 7,500 shares at 26.84 per share price.On Nov 21, 2016, Laurence L Betterley (Chief Financial Officer) sold 20,764 shares at 27.01 per share price.On Nov 21, 2016, Alexander Rosenstein (General Counsel & Corp. Secy) sold 529 shares at 26.80 per share price.
Cardiovascular Systems Inc Last issued its quarterly earnings results on Jan 25, 2017. The company reported $0.03 EPS for the quarter, beating the analyst consensus estimate by $ 0.09. Analyst had a consensus of $-0.06. The company had revenue of $50.04 million for the quarter, compared to analysts expectations of $49.68 million. The companys revenue was up 20.9% compared to the same quarter last year. During the same quarter in the previous year, the company posted $-0.47 EPS.
Cardiovascular Systems, Inc. (NASDAQ:CSII) has received a short term rating of buy from experts at Zacks with a rank of 2. The stock has been rated an average of 1.43 by 7 Brokerage Firm. 5 Wall Street Firms have rated the stock as a strong buys. 1 stock experts have also suggested a buy rating. 1 Brokerage Firms have advised hold.
Cardiovascular Systems, Inc. (NASDAQ:CSII): 5 Brokerage firm Analysts have agreed with the mean estimate for the short term price target of $30 in Cardiovascular Systems, Inc. (NASDAQ:CSII). However, the stock price could fluctuate by $ 1.41 from the estimate as it is suggested by the standard deviation reading. The higher estimate has been put at $32 price target with the lower price estimate is calculated at $28
Cardiovascular Systems, Inc. (NASDAQ:CSII) rose 1.3% or 0.36 points on Tuesday and made its way into the gainers of the day. After trading began at $27.41 the stock was seen hitting $28.45 as a peak level and $27.34 as the lowest level. The stock ended up at $28.05. The daily volume was measured at 703,120 shares. The 52-week high of the share price is $28.45 and the 52-week low is $7.5. The company has a market cap of $915 million.
Cardiovascular Systems, Inc., formerly known as Replidyne Inc., is headquartered in Saint Paul, Minnesota. It is a medical device company focusing on developing and commercializing interventional treatment systems for vascular disease. Its initial product, the Diamondback 360? Orbital Atherectomy System, is a minimally invasive catheter system for the treatment of peripheral arterial disease; and a range of plaque types, including calcified vessel lesions. The Diamondback 360? removes soft and calcified plaque in plaque-lined vessels through the orbital rotation of a diamond grit coated offset crown. The company refined its orbital technology to address the growing market need of providing a safer more effective atherectomy device.